Overview
Simulations Plus
Molecular modeling software plus applications to help individuals with disabilities equals Simulations Plus. The company is a leading provider of applications used by pharmaceutical researchers to model absorption rates for orally dosed drug compounds. Its Words+ subsidiary provides augmentative communication software and input devices that help people with disabilities use computers. Simulations Plus also provides educational software targeted
...
Read More to high school and college students through its FutureLab unit. Pharmaceutical giants GlaxoSmithKline and Roche are among its clients. CEO Walter Woltosz and his wife, Virginia (a director), together own about 40% of the company.
Read Less
Read More to high school and college students through its FutureLab unit. Pharmaceutical giants GlaxoSmithKline and Roche are among its clients. CEO Walter Woltosz and his wife, Virginia (a director), together own about 40% of the company.
Read Less
Shawn O'Connor
See more contacts
Computer Systems Design and Related Services
,
Professional, Scientific, and Technical Services
,
Systems software development services
Accounting, Tax Preparation, Bookkeeping, and Payroll Services
,
Advertising, Public Relations, and Related Services
,
Architectural, Engineering, and Related Services
,
Legal Services
,
Management, Scientific, and Technical Consulting Services
,
Other Professional, Scientific, and Technical Services
,
Scientific Research and Development Services
,
Specialized Design Services
?
?
?
Actual
?
Actual
$70.01 million
Actual
17.52%
-0.07%
$196
AUG
?
?
NASDAQ:SLP
Contacts
Get in Touch with 7 Principals* and 93 Contacts
-
Shawn O'ConnorChief Executive Officer
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of August 31, 2024 (12 month period) in USD
Annual Revenue 2024
$70.01 million
USD
Actual
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Operating Cash | $13 | $22 | $18 |
| Net Investing Cash | -$54 | $7 | $4 |
| Net Financing Cash | -$7 | -$23 | -$8 |
| Net Change in Cash | -$47 | $6 | $15 |
| Cash at Beginning of Period | $58 | $52 | $37 |
| Cash at End of Period | $10 | $58 | $52 |
| Capital Expenditure | -$4 | -$4 | -$4 |
| Assets (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $10 | $58 | $52 |
| Accounts Receivable | $9 | $10 | $14 |
| Inventories | $ | $ | $ |
| Other Current Assets | $20 | $63 | $81 |
| Asset Summary | |||
| Total Current Assets | $39 | $130 | $147 |
| Tangible Fixed Assets | $2 | $2 | $2 |
| Intangible Assets | $59 | $33 | $26 |
| Total Assets | $197 | $186 | $188 |
| Liabilities (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $1 | $0 | $0 |
| Short-Term Debt | $ | $ | $ |
| Other Current Liabilities | $11 | $12 | $8 |
| Liability Summary | |||
| Total Current Liabilities | $12 | $12 | $8 |
| Long-Term Debt | $ | $ | $ |
| Other Long-Term Liabilities | $ | $ | $ |
| Total Liabilities | $14 | $16 | $10 |
| Stakeholder's Equity (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Equity | |||
| Common Stock | $152 | $145 | $139 |
| Retained Earnings | $30 | $25 | $40 |
| Equity Summary | |||
| Total Equity | $182 | $170 | $178 |
| Shares Outstanding | 20,051,134 | 19,937,961 | 20,260,070 |